This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.

It also contains a sub-study to enroll patients with severe COVID-19.

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Seattle, WA

Clinical Trial Center

Ansun Biopharma

The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children. The trial is divided into 5 individual studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies will receive study vaccine as a shot depending on what group they are in.

* Substudy A design: Phase 1 includes participants 6 months through less than 4 years 3 months of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naïve) and will receive 3 doses of study vaccine as their initial series, followed by a fourth dose of study vaccine. Phase 2/3 includes participants 6 months through less than 5 years of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naive) and will receive 1, 2, or 3 doses of study vaccine, depending on what group they are in.
* Substudy B design: includes participants 6 months through less than 5 years of age who have either received 2 or 3 prior doses of BNT162b2 and will receive study vaccine as their third or fourth dose.
* Substudy C design: Phase 1 includes participants 6 months through less than 5 years of age who have received 3 prior doses of BNT162b2 and will receive study vaccine as their fourth dose.
* Substudy D design: includes participants 5 through less than12 years of age who have received 2 or 3 prior doses of BNT162b2 and will receive study vaccine as their third or fourth dose.
* Substudy E design: includes participants 5 through less than 12 years of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naive) and will receive a single dose of study vaccine.

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

Gresham, OR

Syracuse, UT

Paramount, CA

Rolling Hills Estates, CA

Anaheim, CA

Newport Beach, CA

South Office

Newton, KS

AMR Wichita East, KS

West Des Moines Campus

Plano, TX

DFW-East Clinical Site

Edinburg, TX

Dayton, OH

Rochester, NY

Greenville, SC

Kennedy Street NW, Washington

Veracruz, Mexico

Summerville, SC

West Ashley - A

Internal Medicine/Gastroenterology Division - Advanced Endoscopy Research

Division of Reproductive Endocrinology and Infertility

Tampa, FL

Miami, FL

Guayama, PR

Johannesburg, South Africa

Welkom, South Africa

BioNTech

The purpose of this study is to evaluate the efficacy and safety of mRNA-1283 and mRNA-1273 (variant formulations) in adults 50 to 64 years of age without high risk factors for severe COVID-19.

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

Portland, OR

JBR Clinical Research

Riverside, CA

San Diego, CA

Fort Collins

Lincoln, NE

Commons Circle

Lenexa, KY

Grassroots Healthcare - Tulsa, OK

Zomnir Family Medicine - Prosper, TX

Command Family Medicine - Springfield

Round Rock, TX

Chesterfield, MO

Ms. Medicine - Amy Roberts MD and Associates

West Gate Boulevard

Derby City Direct Primary Care - Louisville, KY

Magnolia Family Medicine

Cincinnati, OH

Neighborhood Health - Prairieville, LA

Cullman, AL

The Murphy Clinic - Mandeville, LA

New Orleans, LA

Atlanta, GA

Springer Wellness and Restorative Health

Accel Research Sites - NeuroStudies

Stockbridge, GA

Forest Avenue, Richmond, VA

Mount Pleasant, SC

Newton Family Medicine

Bridgeport, CT

DeLand, FL

Maitland, FL

Jupiter, FL

Miami Lakes, FL

Moderna

The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

AstraZeneca

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of lecanemab in participants with EAD in the Extension Phase and whether the long-term effects of lecanemab as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase. Extension Phase Part B will continue dosing with lecanemab in countries where lecanemab may not be commercially available.

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

British Columbia, Canada

UCSF Memory and Aging Center

Fullerton, CA

Irvine, CA

Denver, CO

Lynn Institute of Oklahoma City East

Austin, TX

Houston, TX

Cordova, TN

Memory Center

Toronto, Canada

Norristown, PA

Stuart, FL

Ocala, FL

Ormond Beach, FL

Bradenton, FL

Port Orange, FL

Newton, MA

Port Charlotte, FL

Clinical Research Center

Brain Matters Research

Sunrise, FL

Hollywood, FL

Palmetto Bay, FL

Gothia Forum - Clinical Trial Center

Macquarie Park, Australia

Clinical Trials Division

Eisai

The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study.

Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).

COVID-19 sub-study:

The purpose of this research sub-study is to explore the immune response following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination in a subset of subjects on long-term ofatumumab 20 mg sc. Note: Novartis is not supplying the SARS-CoV-2 vaccine.

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Find clinical trials for COVID-19 in Portland, OR

Related conditions:

COVID-19 trials near Portland, OR, USA:

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA)

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (Clarity AD)

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS)

Find clinical trials for COVID-19 in .css-epvm6{white-space:nowrap;}Portland, OR

Related conditions:

COVID-19 trials near Portland, OR, USA:

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA)

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (Clarity AD)

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS)

Find clinical trials for COVID-19 in Portland, OR